ticlopidine has been researched along with Aortic Stenosis in 21 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mean aortic regurgitation grade was unchanged." | 2.72 | Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. ( Buellesfeld, L; Felderhoff, T; Gerckens, U; Grube, E; Iversen, S; Laborde, JC; Menichelli, M; Mueller, R; Sauren, B; Schmidt, T; Stone, GW; Zickmann, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 19 (90.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| Nardin, M | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Lynch, DR | 1 |
| Dantzler, D | 1 |
| Robbins, M | 1 |
| Zhao, D | 1 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Musumeci, F | 1 |
| Généreux, P | 1 |
| Cohen, DJ | 1 |
| Mack, M | 1 |
| Rodes-Cabau, J | 1 |
| Yadav, M | 1 |
| Xu, K | 1 |
| Parvataneni, R | 1 |
| Hahn, R | 1 |
| Kodali, SK | 1 |
| Webb, JG | 1 |
| Leon, MB | 1 |
| Kazi, DS | 1 |
| Vavuranakis, M | 2 |
| Kalogeras, K | 1 |
| Vrachatis, D | 1 |
| Kariori, M | 1 |
| Moldovan, C | 1 |
| Mpei, E | 1 |
| Lavda, M | 1 |
| Kolokathis, AM | 1 |
| Siasos, G | 1 |
| Tousoulis, D | 2 |
| Gandhi, S | 1 |
| Schwalm, JD | 1 |
| Velianou, JL | 1 |
| Natarajan, MK | 1 |
| Farkouh, ME | 1 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 1 |
| Kikkert, WJ | 1 |
| Wiegerinck, EM | 1 |
| Stabile, E | 1 |
| Ussia, GP | 2 |
| Sharma, S | 1 |
| Baan, J | 2 |
| Eltchaninoff, H | 1 |
| Rubino, P | 1 |
| Barbanti, M | 2 |
| Tamburino, C | 2 |
| Poliacikova, P | 1 |
| Blanchard, D | 1 |
| Piek, JJ | 1 |
| Delewi, R | 1 |
| Iung, B | 1 |
| Schoechlin, S | 1 |
| Ruile, P | 1 |
| Neumann, FJ | 1 |
| Pache, G | 1 |
| Orvin, K | 1 |
| Eisen, A | 1 |
| Perl, L | 1 |
| Zemer-Wassercug, N | 1 |
| Codner, P | 1 |
| Assali, A | 1 |
| Vaknin-Assa, H | 1 |
| Lev, EI | 1 |
| Kornowski, R | 1 |
| Magkoutis, NA | 1 |
| Fradi, S | 1 |
| Azmoun, A | 1 |
| Ramadan, R | 1 |
| Ben Ouanes, S | 1 |
| Vrachatis, DA | 1 |
| Papaioannou, TG | 1 |
| Ghostine, S | 1 |
| Nijenhuis, VJ | 1 |
| Bennaghmouch, N | 1 |
| Hassell, M | 1 |
| van Kuijk, JP | 1 |
| Agostoni, P | 1 |
| van 't Hof, A | 1 |
| Kievit, PC | 1 |
| Veenstra, L | 1 |
| van der Harst, P | 1 |
| van den Heuvel, AF | 1 |
| den Heijer, P | 1 |
| Kelder, JC | 1 |
| Deneer, VH | 1 |
| van der Kley, F | 1 |
| Onorati, F | 1 |
| Collet, JP | 1 |
| Maisano, F | 1 |
| Latib, A | 1 |
| Huber, K | 1 |
| Stella, PR | 1 |
| Ten Berg, JM | 1 |
| Oguri, A | 1 |
| Ando, J | 1 |
| Watanabe, Y | 1 |
| Kozuma, K | 1 |
| Ishikawa, S | 1 |
| Hosogoe, N | 1 |
| Isshiki, T | 1 |
| Windecker, S | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Mehran, R | 1 |
| Valgimigli, M | 1 |
| Vranckx, P | 1 |
| Welsh, RC | 1 |
| Baber, U | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Giannini, C | 1 |
| De Carlo, M | 1 |
| Guarracino, F | 1 |
| Donne, MG | 1 |
| Benedetti, G | 1 |
| Verunelli, F | 1 |
| Petronio, AS | 1 |
| Scarabelli, M | 1 |
| Mulè, M | 1 |
| Sarkar, K | 1 |
| Cammalleri, V | 1 |
| Immè, S | 1 |
| Aruta, P | 1 |
| Pistritto, AM | 1 |
| Gulino, S | 1 |
| Deste, W | 1 |
| Capodanno, D | 1 |
| Al-Rashid, F | 1 |
| Konorza, TF | 1 |
| Plicht, B | 1 |
| Wendt, D | 1 |
| Thielmann, M | 1 |
| Jakob, H | 1 |
| Erbel, R | 1 |
| Kahlert, P | 1 |
| Grube, E | 1 |
| Laborde, JC | 1 |
| Gerckens, U | 1 |
| Felderhoff, T | 1 |
| Sauren, B | 1 |
| Buellesfeld, L | 1 |
| Mueller, R | 1 |
| Menichelli, M | 1 |
| Schmidt, T | 1 |
| Zickmann, B | 1 |
| Iversen, S | 1 |
| Stone, GW | 1 |
| Brinster, DR | 1 |
| Byrne, M | 1 |
| Rogers, CD | 1 |
| Baim, DS | 1 |
| Simon, DI | 1 |
| Couper, GS | 1 |
| Cohn, LH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve[NCT00530894] | 1,057 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation[NCT02247128] | Phase 4 | 1,016 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation[NCT02224066] | Phase 4 | 65 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| CoreValve® System Australia/New Zealand Clinical Study[NCT01015612] | 634 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause or repeat hospitalization after intervention. (NCT00530894)
Timeframe: duration of study
| Intervention | participants (Number) |
|---|---|
| Inoperable: TAVR | 76 |
| Inoperable: Medical Therapy | 126 |
Death from any cause. (NCT00530894)
Timeframe: 1 Year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 84 |
| High Risk: SAVR | 89 |
| Inoperable: TAVR | 55 |
| Inoperable: Medical Therapy | 89 |
NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort. (NCT00530894)
Timeframe: Baseline to 1 year
| Intervention | Units on scale (Least Squares Mean) |
|---|---|
| High Risk: TAVR | 2.50 |
| High Risk: SAVR | 2.60 |
| Inoperable: TAVR | 2.88 |
| Inoperable: Medical Therapy | 3.92 |
Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure (NCT00530894)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 93 |
| High Risk: SAVR | 97 |
| Inoperable: TAVR | 61 |
| Inoperable: Medical Therapy | 93 |
Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization. (NCT00530894)
Timeframe: 1 year
| Intervention | Days (Mean) |
|---|---|
| High Risk: TAVR | 17.42 |
| High Risk: SAVR | 20.14 |
| Inoperable: TAVR | 25.24 |
| Inoperable: Medical Therapy | 17.04 |
"The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.~KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.~SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status." (NCT00530894)
Timeframe: Baseline and 1 Year
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| KCCQ Overall | SF-12 Physical | SF-12 Mental | |
| High Risk: SAVR | 71.1 | 36.9 | 52.9 |
| High Risk: TAVR | 70.0 | 36.3 | 52.0 |
| Inoperable: Medical Therapy | 46.98 | 29.68 | 46.59 |
| Inoperable: TAVR | 69.41 | 34.85 | 53.31 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
is defined per Valve Academic Research Consortium-1 consensus document (VARC-1), including Cardiovascular and non-cardiovascular mortality. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.038 |
Defined as all death resulting from a cardiac cause or complications of a cardiac procedure and / or death of an unknown cause; this category includes valve-related deaths and non-valve-related cardiac deaths (e.g. congestive heart failure, acute myocardial infarction, documented fatal arrhythmias). (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.035 |
Defined as a composite of all cause death, myocardial infarction(MI) (Q-wave & non-Q-wave), stroke, and re-intervention (defined as any emergent cardiac surgery or percutaneous re-intervention catheter procedure that repairs, otherwise alters or adjusts or replaces a previously implanted valve) (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.099 |
Included Q-wave and non-Q-wave. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.021 |
"Vascular access, delivery and deployment of the device, and retrieval of the delivery system~Correct position of the device in the proper anatomical location (placement in the annulus with no impedance on device function)~Intended performance of the prosthetic valve (aortic valve area > 1.2 cm2 (by echocardiography using the continuity equation) and mean aortic valve gradient < 20 mmHg, without moderate or severe prosthetic valve aortic regurgitation)~Only one valve implanted~No occurrence of in-hospital MACCE" (NCT01015612)
Timeframe: 24-48 hours after the procedure or before the discharge
| Intervention | % of participants with device success (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 52.6 |
Any emergent surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces a previously implanted valve. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.019 |
Is a neurological deficit lasting more than 24 hours, or lasting 24 hours or less with a brain imaging study showing infarction. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|---|
| Medtronic CoreValve® System Implantation | 0.043 |
4 reviews available for ticlopidine and Aortic Stenosis
| Article | Year |
|---|---|
Dual Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve Replacement: Indirect Comparison and Meta-analysis.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination | 2018 |
Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Fibrinolytic Agents; Heart Val | 2013 |
Comparison of Dual-antiplatelet Therapy to Mono-antiplatelet Therapy After Transcatheter Aortic Valve Implantation: Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
5 trials available for ticlopidine and Aortic Stenosis
| Article | Year |
|---|---|
Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Echocardiography; Female; Foll | 2014 |
Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation.
Topics: Administration, Oral; Aortic Valve Stenosis; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2016 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Catheters; Clopidogrel; Drug Therap | 2011 |
Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Bioprosthe | 2006 |
12 other studies available for ticlopidine and Aortic Stenosis
| Article | Year |
|---|---|
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
From innovation to implementation: optimizing long-term outcomes after TAVR.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Ticlopidine; Transcat | 2014 |
Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Aortic Valve Stenosis; Atrial Fibrillation; Clopidogrel; Fem | 2015 |
Antithrombotic therapy after transcatheter aortic valve implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Female; Heart Valve Prosthesis | 2015 |
Early hypoattenuated leaflet thickening and restricted leaflet motion of a Lotus transcatheter heart valve detected by 4D computed tomography angiography.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Clopidogrel; Coronary Angiography; Female; | 2015 |
Platelet reactivity in patients undergoing transcatheter aortic valve implantation.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Combination; Fem | 2016 |
Antiplatelet Therapy in TAVI: Current Clinical Practice and Recommendations.
Topics: Administration, Oral; Anticoagulants; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Therapy, Com | 2016 |
Is Dual Antiplatelet Therapy Necessary in Transcatheter Aortic Valve Implantation?
Topics: Aortic Valve Stenosis; Female; Humans; Male; Platelet Activation; Thrombosis; Ticlopidine; Transcath | 2016 |
Hyper-Response to Clopidogrel in Japanese Patients Undergoing Transcatheter Aortic Valve Implantation.
Topics: Aged, 80 and over; Aortic Valve Stenosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Follow-Up S | 2016 |
Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Clopidogrel; Combined M | 2013 |
Transient increase in pressure gradients after termination of dual antiplatelet therapy in a patient after transfemoral aortic valve implantation.
Topics: Aged; Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Dyspnea; Echocardiograph | 2012 |
Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease ("hybrid approach").
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; Coronary Disease | 2006 |